Last reviewed · How we verify
Zefazone — Competitive Intelligence Brief
marketed
cefmetazole
Insulin-degrading enzyme
Metabolic
Small molecule
Live · refreshed every 30 min
Target snapshot
Zefazone (CEFMETAZOLE).
Comparator set (2 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Zefazone TARGET | CEFMETAZOLE | marketed | cefmetazole | Insulin-degrading enzyme | 1989-01-01 | |
| Coly-Mycin S | tonzonium | Par Sterile Products | marketed | tonzonium | Insulin-degrading enzyme | 1962-01-01 |
| Infuvite Adult | BIOTIN | Pfizer | marketed | Vitamin C [EPC] | Insulin-degrading enzyme | 1953-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (cefmetazole class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Zefazone CI watch — RSS
- Zefazone CI watch — Atom
- Zefazone CI watch — JSON
- Zefazone alone — RSS
- Whole cefmetazole class — RSS
Cite this brief
Drug Landscape (2026). Zefazone — Competitive Intelligence Brief. https://druglandscape.com/ci/cefmetazole. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab